There are currently 10 active clinical trials seeking participants for Bleeding research studies. The states with the highest number of trials for Bleeding participants are California, Texas, New York and Florida.
Obsidio™ Conformable Embolic Registry
NCT06170619
Recruiting
OCCLUDE is a prospective, post-approval, open-label, single arm, multi-center US registry of patients who undergo embolization with Obsidio™ Conformable Embolic. The purpose of this Registry is to assess effectiveness and safety outcomes of subjects who undergo embolization with Obsidio.
Gender:
All
Ages:
18 years and above
Trial Updated:
06/21/2024
Locations: Christiana Hospital, Newark, Delaware +1 locations
Conditions: Hypervascular Tumors, Bleeding, Hemorrhage
Register for Updates
HEAL-LAA Clinical Trial
NCT05809596
Recruiting
The primary objective of this study is to collect real-world data on WATCHMAN FLX™ Pro Left Atrial Appendage Closure (LAAC) Device in patients with non-valvular atrial fibrillation.
Gender:
All
Ages:
18 years and above
Trial Updated:
06/18/2024
Locations: University of Alabama Medical Center, Birmingham, Alabama +50 locations
Conditions: Atrial Fibrillation, Bleeding, Stroke
Register for Updates
Amulet™ ADVANCE LAA
NCT05997446
Recruiting
This is a prospective, multicenter, observational study intended to characterize real-world outcomes on the commercially available Amulet device in the United States. The study will enroll approximately 1000 subjects at up to 50 US clinical sites. Subjects will be followed through 24 months in accordance with each site's standard care practices.
Gender:
All
Ages:
18 years and above
Trial Updated:
06/03/2024
Locations: Arizona Arrhythmia Research, Phoenix, Arizona +26 locations
Conditions: Atrial Fibrillation, Stroke, Bleeding
Register for Updates
Amplatzer Amulet LAAO vs. NOAC
NCT04226547
Recruiting
The objective of this trial is to evaluate the safety and effectiveness of the Amulet LAA occluder compared to NOAC therapy in patients with non-valvular AF at increased risk for ischemic stroke and who are recommended for long-term NOAC therapy. The clinical investigation is a prospective, randomized, multicenter active control worldwide trial. Subjects will be randomized in a 1:1 ratio between the Amulet LAA occlusion device ("Device Group") and a commercially available NOAC medication ("Cont... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
04/15/2024
Locations: University Hospital - Univ. of Alabama at Birmingham (UAB), Birmingham, Alabama +126 locations
Conditions: Atrial Fibrillation, Stroke, Bleeding
Register for Updates
Tranexamic Acid to Reduce Contraceptive-related Bleeding Side Effects
NCT06000423
Recruiting
This randomized double blinded trial seeks to determine whether tranexamic acid (TXA) is an efficacious treatment for contraceptive induced menstrual changes (CIMC) including irregular, bothersome bleeding caused by the etonogestrel subdermal contraceptive implant (ENG implant). Participants will be randomized into the TXA treatment arm or a placebo. They will begin taking the medication after three consecutive days of bleeding. Participants will track their bleeding using an automated text mess... Read More
Gender:
Female
Ages:
Between 15 years and 45 years
Trial Updated:
04/01/2024
Locations: Oregon Health & Science University, Portland, Oregon
Conditions: Bleeding, Contraceptive Device; Complications
Register for Updates
PK, Safety Study of 90-Day Use of Vaginal Rings Containing Dapivirine and Levonorgestrel
NCT05041699
Recruiting
A double-blind, randomized trial (1:1) to characterize the local and systemic pharmacokinetics (PK) of two DPV-LNG vaginal ring formulations
Gender:
Female
Ages:
Between 18 years and 45 years
Trial Updated:
03/06/2024
Locations: Oregon Health & Science University, Portland, Oregon +1 locations
Conditions: Pharmacokinetics, Safety Issues, Bleeding
Register for Updates
Anticoagulation for New-Onset Post-Operative Atrial Fibrillation After CABG
NCT04045665
Recruiting
The primary objective of this study is to evaluate the effectiveness (prevention of thromboembolic events) and safety (major bleeding) of adding oral anticoagulation (OAC) to background antiplatelet therapy in patients who develop new-onset post-operative atrial fibrillation (POAF) after isolated coronary artery bypass graft (CABG) surgery. All patients with a qualifying POAF event, who decline randomization, will be offered the option of enrollment in a parallel registry that captures their ba... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
11/08/2023
Locations: CHI St. Vincent, Arkansas, Little Rock, Arkansas +89 locations
Conditions: Atrial Fibrillation, Stroke, Bleeding
Register for Updates
Transfusion of Pathogen Reduced Cryoprecipitated Fibrinogen to Expedite Product Availability in Perioperative Bleeding
NCT05711524
Recruiting
The goal of this quality improvement study is to compare pathogen-reduced cryoprecipitate with traditional cryoprecipitate in liver transplant and cardiovascular patients. The investigators hypothesize that by having immediate access to a readily available thawed blood product that replaces fibrinogen (the main substrate of a blood clot), early bleeding can be treated before it escalates into uncontrolled hemorrhage, and therefore additional blood products, like platelets, plasma and red blood c... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
09/29/2023
Locations: New York-Presbyterian Hospital/Weill Cornell Medical Center, New York, New York
Conditions: Hypofibrinogenemia, Bleeding
Register for Updates
Extended Cold Stored Apheresis Platelets in Cardiac Surgery Patients
NCT05220787
Recruiting
This trial is being performed to evaluate the feasibility of the study protocol and to test the efficacy and safety of platelets stored at cold conditions (1-6°C) in 100% plasma for 10-14 days (CSP) in cardiac surgery patients who are actively bleeding and require platelet transfusion.
Gender:
All
Ages:
Between 18 years and 100 years
Trial Updated:
07/26/2023
Locations: Swedish Medical Center - Cherry Hill, Seattle, Washington
Conditions: Hemorrhage, Platelets; Defect, Bleeding, Surgical Blood Loss
Register for Updates
The Neonatal Hemorrhagic Risk Assessment in Thrombocytopenia
NCT04598750
Recruiting
This is a prospective observational study designed to evaluate Immature Platelet Fraction or Immature Platelet Count and Platelet Function Analyzer-100/200 Closure Time-ADP (in vitro bleeding time) as markers of bleeding risk in thrombocytopenic preterm neonates admitted to the Neonatal Intensive Care Unit.
Gender:
All
Ages:
1 day and above
Trial Updated:
03/21/2023
Locations: Boston Children's Hospital, Boston, Massachusetts +7 locations
Conditions: Neonatal Thrombocytopenia, Bleeding
Register for Updates